Alok Srivastava on fitusiran for patients with haemophilia A and B

Professor Alok Srivastava tells us about two clinical trials being published in The Lancet and The Lancet Haematology on a new siRNA therapy called fitusiran for patients with haemophilia A and B. Read the two trials: Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH) https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00284-2/fulltext?dgcid=buzzsprout_icw_podcast_buzzsprout_general Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B) https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00037-6/fulltext?dgcid=buzzsprout_icw_podcast_buzzsprout_general Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv The Lancet Haematology in conversation with...  is part of the Lancet Group podcast offering.  Editorial team: editor-in-chief Lan-Lan Smith, deputy editor Emma Cookson, and senior editor Daniela Marin Podcast editing: Matteo Simonetti Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering.  Find the best science for better lives at www.thelancet.com Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv